Skip to main content

GT Restructuring Appointed at Biotech Company Mologen in Insolvency

Berlin, December 11, 2019 – GT Restructuring, the restructuring unit of Greenberg Traurig in Germany, has been appointed at the biopharmaceutical company Mologen AG in its insolvency proceedings. Christian Köhler-Ma runs the Berlin-based company with all 31 employees as provisional insolvency administrator. He has started initial talks with interested investors.

The internationally active Mologen AG develops DNA-based drugs for the activation of the body’s own immune system to fight cancer and infectious diseases. The company was founded in 1998 and has been listed on the Frankfurt Stock Exchange since 2009. Following a clinical study on a new drug, the results of which were unsatisfactory, financing problems arose.

There are several interested parties for the operation or individual parts and preparations, so that Christian Köhler-Ma is confident of finding a constructive solution.

About Greenberg Traurig, LLP: Greenberg Traurig, LLP (GT) has approximately 2,100 attorneys in 41 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. Web: Twitter: @GT_Law.